Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study (CYPRESS)

AbstractBackgroundMutations in the L/M cone opsin gene array cause abnormally high perceived retinal contrast and the development of myopia. Environmental factors may also lead to high visual contrast and cause myopia. Diffusion optics technology (DOT) lenses are designed to reduce contrast signalli...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:British journal of ophthalmology Ročník 107; číslo 11; s. 1709 - 1715
Hlavní autori: Rappon, Joe, Chung, Carol, Young, Graeme, Hunt, Christopher, Neitz, Jay, Neitz, Maureen, Chalberg, Thomas
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: BMA House, Tavistock Square, London, WC1H 9JR BMJ Publishing Group Ltd 01.11.2023
BMJ Publishing Group LTD
Predmet:
Clinical science
Clinical Trial
Haplotypes
Hypotheses
Light
Myopia
Optics
Photoreceptors
Public health
Treatment other
Vision
Visual acuity
Visual impairment
X chromosomes
Clinical Trial
Vision
Treatment other
ISSN:0007-1161, 1468-2079, 1468-2079
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:AbstractBackgroundMutations in the L/M cone opsin gene array cause abnormally high perceived retinal contrast and the development of myopia. Environmental factors may also lead to high visual contrast and cause myopia. Diffusion optics technology (DOT) lenses are designed to reduce contrast signalling in the retina and slow myopia progression.MethodsThe Control of Myopia Using Peripheral Diffusion Lenses Efficacy and Safety Study (CYPRESS, NCT03623074) is a 36-month, multicentre, randomised, controlled, double-masked trial evaluating two investigational spectacle lenses versus control lenses in myopic children aged 6–10, with a planned interim analysis at 12 months. The primary endpoints are change from baseline in axial length (AL) and spherical equivalent refraction (SER).Results256 children (58% female; mean age at screening, 8.1 years) were dispensed spectacles. Across all groups, baseline averages were AL 24.02 mm (SD±0.77 mm), SER −2.01 D (SD±0.9 D) using manifest refraction, and SER −1.94 D (SD±1.0 D) using cycloplegic autorefraction. At 12 months, mean difference in SER progression for test 1 versus control was −0.40 D (p<0.0001), representing a 74% reduction and −0.32 D for Test 2 (p<0.0001), representing a 59% reduction. The difference in AL progression for test 1 versus control was 0.15 mm (p<0.0001) and test 2 versus control was 0.10 mm (p=0.0018).Conclusion12-month results from this ongoing trial demonstrate the safety and effectiveness of DOT spectacles for reducing myopic progression.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:0007-1161
1468-2079
1468-2079
DOI:10.1136/bjo-2021-321005